Related Experiment Video
Updated: Jul 13, 2026

Establishment of a Surgically-induced Model in Mice to Investigate the Protective Role of Progranulin in Osteoarthritis
Published on: February 25, 2014
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations
Vivianna M Van Deerlin1, Elisabeth McCarty Wood, Peachie Moore
1Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA.
Background:
Patients with frontotemporal dementia due to mutation of progranulin may have a distinct phenotype.
Objective:
To identify distinct clinical and pathologic features of patients with frontotemporal dementia who have mutations of progranulin (GRN).
Design:
Retrospective clinical-pathologic study.
Setting:
Academic medical center.
Patients:
Twenty-eight patients with frontotemporal dementia, including 9 with GRN mutations (4 autopsy cases and 5 with only clinical information) and 19 with the identical pathologic diagnosis--frontotemporal lobar degeneration with ubiquitin-positive and tau-negative inclusions (FTLD-U)--and no GRN mutations.
Main Outcome Measures:
Demographic, symptom, neuropsychological, and autopsy characteristics.
Results:
Patients with and without a GRN mutation have similar demographic features, although family history is significantly more common in patients with frontotemporal dementia and a GRN mutation. Both patient groups have frequent social and personality complaints. Neuropsychological evaluation reveals a significant recognition memory deficit in patients with a GRN mutation but a significant language deficit only in patients without a GRN mutation. At autopsy, the semiquantitative burden of ubiquitin abnormality is relatively modest in both groups of patients.
Conclusion:
Patients with a GRN mutation differ clinically from those with the same pathologic diagnosis but no GRN mutation.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Huntington Disease l: Introduction

